home / stock / esalf / esalf quote
Last: | $40.005 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $40.005 |
High: | $0 |
Low: | $0 |
Volume: | 4 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$40.005 | $0 | $40.005 | $0 | $0 | 4 | 04-26-2024 |
$40.005 | $40.005 | $40.005 | $40.005 | $40.005 | 310 | 04-25-2024 |
$40.1 | $40.31 | $40.1 | $41.12 | $40.1 | 31,467 | 04-24-2024 |
$38.71 | $38.71 | $38.71 | $38.71 | $38.71 | 570 | 04-22-2024 |
$38.95 | $38.79 | $38.95 | $38.95 | $38.79 | 925 | 04-19-2024 |
$37.53 | $38.1 | $37.53 | $38.1 | $37.53 | 2,125 | 04-18-2024 |
$38.11 | $38.18 | $38.11 | $38.18 | $38.11 | 899 | 04-17-2024 |
$39 | $0 | $39 | $0 | $0 | 14 | 04-16-2024 |
$39 | $0 | $39 | $0 | $0 | 37 | 04-15-2024 |
$39 | $0 | $39 | $0 | $0 | 90 | 04-12-2024 |
$39 | $39 | $39 | $39 | $39 | 120 | 04-11-2024 |
$39.2 | $39.19 | $39.2 | $39.2 | $38.59 | 2,260 | 04-10-2024 |
$40.375 | $0 | $40.375 | $0 | $0 | 43 | 04-09-2024 |
$40.375 | $40.365 | $40.375 | $40.375 | $40.365 | 288 | 04-08-2024 |
$40.12 | $40.12 | $40.12 | $40.12 | $40.12 | 100 | 04-05-2024 |
$40.3 | $40.31 | $40.3 | $40.31 | $39.15 | 750 | 04-04-2024 |
$39.88 | $39.88 | $39.88 | $39.88 | $39.88 | 1,630 | 04-03-2024 |
$40.135 | $0 | $40.135 | $0 | $0 | 45 | 04-02-2024 |
$40.135 | $40.135 | $40.135 | $40.135 | $40.135 | 320 | 04-01-2024 |
$41.682 | $42.33 | $41.682 | $42.33 | $41.225 | 392 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infu...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the ...